KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market
October 19 2021 - 7:30AM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, today announced that its shares of common stock have
been approved for listing to The Nasdaq Global Select Market.
Trading on the exchange will commence effective with the open of
business on October 19, 2021, under KemPharm’s current ticker
symbol, “KMPH”.
“KemPharm’s advancement to The Nasdaq Global
Select Market continues a year of tremendous growth and
accomplishment for our company during which time we transformed our
business, solidified our financial position and, most importantly
with AZSTARYS®, succeeded in bringing forth to market the first
truly differentiated ADHD medication in years,” said Travis C.
Mickle, Ph.D., President and Chief Executive Officer of KemPharm.
“The Nasdaq Global Select Market is recognized as having the
highest initial listing standards of any exchange in the world and
is considered a mark of achievement and stature for qualified
companies. KemPharm is honored to be amongst this class of company,
and we are excited by the opportunity to attract a new echelon of
potential investors to our stock.”
KemPharm was previously listed on The Nasdaq
Capital Market, following its uplisting to the exchange in January.
The Nasdaq Global Select Market consists of 1,450 stocks that meet
Nasdaq's strict financial and liquidity requirements and corporate
governance standards on both an initial and continuing basis.
About AZSTARYS:
AZSTARYS is an FDA-approved, once-daily product
for the treatment of attention deficit hyperactivity disorder
(ADHD) in patients age six years or older. AZSTARYS consists of
SDX, KemPharm’s prodrug of d-methylphenidate (d-MPH), co-formulated
with immediate release d-MPH.
The complete approved prescribing information
for AZSTARYS may be downloaded in PDF format
here:https://kempharm.com/wp-content/uploads/2021/03/AZSTARYS-Master-Label-Final_20210302.pdf
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). KemPharm’s lead
clinical development candidate for the treatment of SUD, KP879, is
based on its prodrug of d-methylphenidate, known as
serdexmethylphenidate (SDX). In addition, KemPharm has received FDA
approval for AZSTARYS®, a new once-daily treatment for ADHD in
patents age six years and older, and for APADAZ®, an
immediate-release combination product containing benzhydrocodone, a
prodrug of hydrocodone, and acetaminophen. For more information on
KemPharm and its pipeline of prodrug product candidates visit
www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook
and YouTube.
Caution Concerning Forward Looking
Statements:
This press release may contain forward-looking
statements made in reliance upon the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements include all statements that do not
relate solely to historical or current facts and can be identified
by the use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to KemPharm and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning KemPharm’s business are described in detail
in KemPharm’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2021, and KemPharm’s other filings with the Securities and
Exchange Commission. KemPharm is under no obligation to, and
expressly disclaims any such obligation to, update or alter its
forward-looking statements, whether as a result of new information,
future events or otherwise.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024